Toho Holdings (8129) · RiskRestated
Risk from Misalignment Between Consumption Tax Revisions and Drug Price Revisions
First written in FY2018. 2 of 3 entries say "Restated". Latest entry: FY2020.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Earnings impact on the dispensing business from consumption tax rate changes and differences in drug price pass-throughA theme 7 companies write about · 7 as a headwind · 0 as a tailwind
4 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020RestatedAnnual report
「If consumption tax rates are revised in the future but the drug price schedule is not revised in line with the rate of change, the Group's results could be affected.」
It continues to identify as a risk the impact on the pharmacy business if consumption tax revisions and drug price schedule revisions are not linked. - FY2019RestatedAnnual report
「Accordingly, if consumption tax rates are revised in the future but the drug price schedule is not revised in line with the rate of change, the Group's results could be affected.」
It continues to identify as a risk the impact on the pharmacy business if consumption tax revisions and drug price schedule revisions are not linked. - FY2018First statedAnnual report
「Accordingly, if consumption tax rates are revised in the future but the drug price schedule is not revised in line with the rate of change, the Group's results could be affected.」
It identifies as a risk the burden of consumption tax when purchasing pharmaceuticals in the pharmacy business, and the impact on results if future consumption tax revisions are not reflected in drug prices.